Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

ith OGX-011 plus docetaxel. Secondary endpoints included determining objective response and duration of response in those patients with measurable disease at baseline, determining the tolerability and toxicity of weekly OGX-011 and docetaxel when administered in combination, measuring the effect of OGX-011 plus docetaxel or docetaxel alone on serum clusterin levels and describing time to progression and overall patient survival. Baseline characteristics were well balanced between the treatment arms. In addition to the survival results presented and based on a median follow-up of 32 months, data were presented as summarized below.

    -   The OGX-011 plus docetaxel arm met the primary endpoint of the trial
        given that 58% of patients treated with OGX-011 plus docetaxel
        achieved confirmed PSA declines of 50% or greater.

    -   The median number of treatment cycles administered was 9 cycles in
        the OGX-011 plus docetaxel arm compared to 7 cycles in the docetaxel
        arm. The majority of patients either completed all 10 cycles of trial
        treatment (34 patients) or discontinued trial treatment based on
        disease progression (23 patients) or adverse events (14 patients).

    -   Fewer than half as many patients in the OGX-011 plus docetaxel arm
        (7 patients) discontinued trial treatment early for PSA progression
        and/or objective disease progression compared to the docetaxel arm
        (16 patients). Of the 9 patients in the OGX-011 arm that discontinued
        for adverse events, 7 of these patients experienced adverse events
        during the 8th and 9th treatment cycles.

    -   Evidence of a pharmacodynamic effect in the OGX-011 plus docetaxel
        arm was observed with statistically significant declines in serum
        clusterin levels within the first cycle of trial treatment when
        compared to levels in the docetaxel arm. OGX-011 has been shown to
        
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
(Date:7/10/2014)... WASHINGTON D.C., June 17, 2014 Using microscopic ... of specific gases, researchers at MIT,s Quantum Photonics ... detection levels in the parts-per-billion range. Optical sensors ... to their high signal-to-noise ratio, compact, lightweight nature, ... optical gas sensors had been developed before, the ...
(Date:7/10/2014)... RICHLAND, Wash. The lithium-ion batteries that power our ... run longer on a single charge with the help ... the porous material to replace the graphite traditionally used ... more than 10 times the energy storage capacity of ... lithium-ion battery electrode was published today in Nature ...
(Date:7/10/2014)... see the two universities and NPL collaborate to bring ... industry and their complementary academic strengths., Working with BIS ... the scientific priorities of the UK. The establishment of ... high-calibre PhD students, will provide a pipeline of skilled ... of the Laboratory will be grown through the creation ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 2Universities of Surrey and Strathclyde selected as strategic partners in the future operation of the National Physical Laboratory 3
... DALLAS, Nov. 6 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ... the Rodman & Renshaw Annual Global Investment Conference to ... Hotel. Jeffrey B. Davis, CEO of,Access is scheduled to ... Time, and will give a corporate overview and discuss ...
... Nov. 6 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced its financial results for the third quarter ... The net loss available to common shareholders ...
... 6 EntreMed, Inc.,(Nasdaq: ENMD ), a ... cancer and inflammatory diseases, today,reported results for the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ), Revenues for ... for the comparable period a year ago. The ...
Cached Biology Technology:Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 2Advanced Life Sciences Announces Third Quarter 2008 Financial Results 3Advanced Life Sciences Announces Third Quarter 2008 Financial Results 4Advanced Life Sciences Announces Third Quarter 2008 Financial Results 5Advanced Life Sciences Announces Third Quarter 2008 Financial Results 6Advanced Life Sciences Announces Third Quarter 2008 Financial Results 7Advanced Life Sciences Announces Third Quarter 2008 Financial Results 8Advanced Life Sciences Announces Third Quarter 2008 Financial Results 9Advanced Life Sciences Announces Third Quarter 2008 Financial Results 10Advanced Life Sciences Announces Third Quarter 2008 Financial Results 11EntreMed Reports Third Quarter 2008 Financial Results 2EntreMed Reports Third Quarter 2008 Financial Results 3EntreMed Reports Third Quarter 2008 Financial Results 4EntreMed Reports Third Quarter 2008 Financial Results 5
(Date:7/10/2014)... 27, 2014  Pomerantz LLP has filed a ... or the "Company")(NYSE-MKT: PVCT) and certain of its ... District Court, Middle District of Tennessee ... a class consisting of all persons or entities ... December 17, 2013 and May 22, 2014, both ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
(Date:7/10/2014)... , July 8, 2014 ... a new design win (DW). An Asian OEM has selected ... mass production start in August 2014.   FPC ... OEM, which has a planned date for start of mass ... ramp order of SEK 5M, for delivery in the first ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... scientists have produced a first-of-its kind map that details the ... and regional-scale forest canopy maps, the new map is the ... method. The map, based on data collected by NASA,s ... inventory of how much carbon the world,s forests store and ...
... ( www.ucr.edu ) -- A year ago, Sharon Walker, ... the UC Riverside Bourns College of Engineering, flew to ... water quality and sustainability issues in a similarly arid ... deep familiarity with Skype, a baby daughter and a ...
... The Association for Molecular Pathology (AMP) participated in ... and Radiological Health (CDRH) public,meeting on the oversight ... President of AMP,served on the second panel of ... Lyon, Chair of the AMP Professional Relations Committee, ...
Cached Biology News:First-of-its-kind map details the height of the globe's forests 2A baby, Skype and water research partnership with Israel 2A baby, Skype and water research partnership with Israel 3AMP presents at FDA meeting on regulating diagnostics 2AMP presents at FDA meeting on regulating diagnostics 3